about
Clinical significance in the change of decline in ALSFRS-RProteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosisClinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice.Job-related formaldehyde exposure and ALS mortality in the USADesign and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosisSafety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialBeing PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?The PRO-ACT database: design, initial analyses, and predictive featuresA high-density genome-wide association screen of sporadic ALS in US veteransSelecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisSafety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.Amyotrophic lateral sclerosis: an emerging era of collaborative gene discoveryHow common are ALS plateaus and reversals?Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients.Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach.Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosisHypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trialDiscovery and verification of amyotrophic lateral sclerosis biomarkers by proteomicsSafety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.Vitamin E intake and risk of amyotrophic lateral sclerosis.Disease burden in upper motor neuron syndromes: a survey of patient perspectives.Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosisInosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.Arimoclomol: a potential therapy under development for ALS.Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosisSystemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosisDepression in amyotrophic lateral sclerosis.Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).Uric acid levels predict survival in men with amyotrophic lateral sclerosis.Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.New considerations in the design of clinical trials for amyotrophic lateral sclerosisPre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis
P50
Q22305679-BF9C02AE-E96E-4BFA-B1DC-C6AE656B0686Q24678722-838E9DB8-0C82-4115-971A-BCD3BF1E02ACQ26823418-D11E335D-D4B9-42DE-B170-5D8E181690C6Q27340206-A664B406-85F7-4CAD-8B04-703DDFAA8477Q28385745-06555428-07C9-4134-B4EF-78402F01B550Q28486263-7DC9B123-AEC8-446C-A763-4C0491602227Q28538939-C255C68B-7046-4829-98C1-BDDAED2433E3Q28649394-C0CE3A10-168C-428E-A5A7-8F4282389F8DQ28651661-EDFBBDE0-5CBF-4E20-92DD-3D33424E572CQ28730882-3A3D58C7-776D-46A4-B5B3-763873316A9BQ30275531-D6259372-C639-49DB-B2CA-8CDA6A930501Q30276131-39AA4134-90B0-4FE0-BE6E-8F988E535DFAQ30432762-EB71937E-7042-4EDD-9AA1-72CBD46673F7Q30444138-991F6435-903B-4B55-826E-3916168D0BE7Q30488673-592A7A1B-CCB9-438F-9BB9-D0841028E590Q30866592-2BC96057-C386-432D-A1F7-CF8CB0927F93Q33741393-1DC0658A-1D69-4B3B-8E95-2B954224C5FAQ34128577-1DF40ACA-DAD6-47C9-B260-1CB0CE0D4E95Q34128577-BA276541-791C-4B89-B200-25F223379672Q34168523-3A3D05FC-8BCE-4E32-8AF9-F032DB29C6E4Q34187004-0056BC3E-FFA2-4114-AF36-45515B3436C3Q34251334-4099D8B8-31A3-4F70-992C-2288FB9B569EQ34285662-1A12BAE0-8580-4606-897B-80F7BD4652AEQ34436090-2BF45D64-4E9E-492B-AC1F-80E5A1A09DADQ34512451-5F1D785C-CC2C-4A3E-8EBF-2869E6E438DEQ34552441-28A76514-3AD9-4E74-99FB-065AD9AD733BQ34569707-3D5A5424-ADD2-48EF-867C-9F8FB31B3058Q34593152-46CD2825-E7D6-44E6-9C48-935269F52D39Q34610044-B48DDD00-C0EA-4C6F-9B51-0494F8CDEE92Q34658560-47654985-4707-4E62-B9DA-0896F7F09624Q34669342-7DEB6E40-2F24-45ED-84B7-F52C33D2F33DQ35014529-BC41260E-C665-46D7-90BC-D7FE978C1393Q35028404-78A6FA11-763F-4AE3-B3D2-267BDE5F7092Q35110299-FDE3C1ED-4EA0-47D0-A919-CD3C272167DCQ35156359-56FDA77A-8BD5-4A87-B5E7-D6F0B47F4000Q35163766-FB300B28-BEB3-4F3F-8C9D-95A347778B11Q35610160-84079210-E202-4791-9B85-A948C75F07CCQ35638492-D5EDB67C-B12A-45E2-BCAA-19DF84039ED1Q35783279-7BF6FC34-C355-47C3-B229-77EB9C9ED298Q35910744-F14FA2AC-BB58-4F9D-9571-BE382734EE5F
P50
name
Merit E Cudkowicz
@en
Merit E Cudkowicz
@nl
type
label
Merit E Cudkowicz
@en
Merit E Cudkowicz
@nl
prefLabel
Merit E Cudkowicz
@en
Merit E Cudkowicz
@nl